Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

RPS pledges to make profession 'more inclusive'

The Royal Pharmaceutical Society (RPS) has launched a 'pledge' for pharmacy to help make the profession inclusive, create a culture of belonging, and support pharmacy teams’ wellbeing.

“Individuals and organisations can sign up to show their support for creating change in the workplace through a series of actions that will enable a safe and supportive working culture for all,” the Pharmaceutical Services Negotiating Committee (PSNC) said in an update.


The pledge was created through discussions with organisations across the profession, including PSNC, on current workplace culture and what needs to change.

“Its values are aligned with the Joint Plan for Inclusive Pharmacy Practice in England launched in March 2021 and the actions were informed by the results of the annual RPS Workforce Wellbeing Survey,” the RPS said.

PSNC chief executive Simon Dukes said: “PSNC supports the RPS Inclusion and Wellbeing Pledge. It reconfirms our commitment to work closely with our fellow national pharmacy representatives and the NHS to help community pharmacy to remain a sector that is accessible for everyone.”

RPS president Sandra Gidley said: “We want to create a positive culture in pharmacy that is actively inclusive and protects wellbeing. This will require concerted and collective action from across the profession.

“Signing the RPS Inclusion and Wellbeing Pledge is an important step on the journey towards creating a culture at work that values inclusivity and wellbeing. The pledge can be signed by individuals, teams and organisations, and is a commitment to reflect on personal behaviours, or organisational practices and policies, that will improve the workplace environment.”

Dr Keith Ridge CBE, chief pharmaceutical officer for England said: “I would encourage pharmacists across all NHS services to join together and sign the pledge to demonstrate your personal commitment to workforce wellbeing and inclusive pharmacy practice.”

More For You

Astrazeneca Office Building  Outlook

British Medical Journal has found data discrepancy during the crucial clinical trials of AstraZeneca's heart drug ticagrelor.

iStock

Top medics question trials of AstraZeneca's anti-clotting pill

The effectiveness of anti-clotting pill ticagrelor is now under a cloud, with some experts claiming that AstraZeneca misreported data when the trials were conducted more than a decade ago.

Sold as Brilinta, the pill was approved for use on the NHS in 2011 after trials claimed it could prevent one in five deaths after a heart attack, and the generic versions of the drug are scheduled for this year.

Keep ReadingShow less
Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

iStock

Pensions Ombudsman probing Boots pension dispute

The Pensions Ombudsman has begun an investigation into the decision by the Trustees of Boots Pension Scheme to remove members' option to retire on an unreduced pension at age 60.

According to the Pharmacists' Defence Association (PDA), the ombudsman has decided to take a ‘lead case’ approach, as several members have been affected by the issue.

Keep ReadingShow less
23andMe

More than 150,000 UK residents had their personal information taken by hackers during a data breach in 2023.

iStock

UK watchdog fines 23andMe £2.31m for data breach

Genetic testing firm 23andMe has been fined £2.31 million by a UK watchdog over a 2023 data breach, when the personal information of seven million people across the world was stolen.

The Information Commissioner's Office (ICO) said the California-based company, which later filed for bankruptcy, failed to put adequate measures in place to secure sensitive user data.

Keep ReadingShow less
Henry Gregg, new Chief Executive of the National Pharmacy Association.
Henry Gregg
Henry Gregg

Community pharmacy voices need to be ‘heard really loud’, new NPA chief tells Pharmacy Business

Henry Gregg, the new chief executive of the National Pharmacy Association (NPA), believes community pharmacies have a right to have insight into discussions relating to the pharmacy funding contract.

Currently, Community Pharmacy England (CPE) solely negotiates the elements of the Community Pharmacy Contractual Framework (CPCF) with the Department of Health and Social Care (DHSC) and NHS England.

Keep ReadingShow less
Patient care

The NHS said the benefits were "too small to justify the additional cost"

NHS rejects Alzheimer's drugs shown to delay early-stage of disease

Two new treatments for Alzheimer's disease will not be offered on the NHS due to high costs and "too small" benefits.

Donanemab and Lecanemab have been hailed as breakthrough treatments for slowing down the symptoms of early-stage Alzheimer's, the most common type of dementia.

Keep ReadingShow less